Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
More than 90,000 Canadians—or one in 400 people across Canada—live with multiple sclerosis (MS),1 a neurodegenerative, chronic condition that affects the central nervous system.2 Despite decades of...
MONTRÉAL, March 21, 2024 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by...
MONTREAL, Dec. 5, 2023 /CNW/ - Novartis Canada announces that Mark Vineis has been appointed to the role of Country President, effective as of January 1, 2024. Mark brings a wealth of experience and...
Health technology assessment (HTA) agencies reinforce the therapeutic value of PLUVICTO™ and need for new approaches to treat advanced prostate cancer Positive HTA recommendations for reimbursement...
Novartis has a long-standing history in Canada, and is committed to delivering improved outcomes for millions of patients. In 2022, Novartis invested a total of $450 million in Canada. The office has ...
Ontario joins Quebec, Alberta and Saskatchewan to fund gene-based treatment for previously untreatable genetic retinal conditions1 Luxturna® is the first and only pharmacological treatment for an...
Novartis has begun collaborating with seven clinics across the province to support the prevention, identification and management of atherosclerotic cardiovascular disease (ASCVD) In Ontario,...
Alberta centre first in Canada to treat patients with Luxturna® (voretigene neparvovec) through public drug plan funding As a one-time gene therapy, Luxturna® provides healthy copies of the RPE65...
Quebec leads the way as the first province to reimburse Luxturna® (voretigene neparvovec) for previously untreatable inherited retinal disease1 Approved by Health Canada in 2020, Luxturna® is a...
Luxturna® (voretigene neparvovec) is a one-time gene therapy that provides healthy copies of the RPE65 gene for retinal cells that are lacking the normally functioning gene1 DORVAL, QC, Sept. 20,...
Scemblix provides a new option for chronic myeloid leukemia (CML) patients who have had two or more previous tyrosine kinase inhibitor (TKI) treatments1 New mechanism of action with Scemblix...
Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for Canadians affected by advanced lung cancer DORVAL, QC, June 8, 2022 /CNW/...
The product of over 120 consultations with health care practitioners, the Novartis Pro Portal is a one-stop digital hub developed to provide tailored, real-time support in daily practice. DORVAL, QC, ...
Kesimpta® is the first and only B-cell therapy for RRMS that can be administered by patients in the safety and convenience of their home1 Kesimpta® delivers superior efficacy with a favourable safety ...
Beovu® is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the loading phase with no compromise in efficacy.1,2 While wet...
In Canada, cardiovascular disease accounted for more than 52,000 deaths between 2015 and 20191. Almost 80 per cent of deaths from cardiovascular disease are preventable2. Novartis is joining forces...
Public reimbursement is effective October 20th and will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux Zolgensma is the...
Public reimbursement under the Régie de l'assurance maladie du Québec, effective October 20th will apply for children with SMA following the recommendation from the Institut national d'excellence en...
This World Sight Day, Fighting Blindness Canada and the Canadian Council of the Blind have partnered with Novartis Canada to launch "All Eyes on You", a campaign urging Canadians to lend their voices ...
DORVAL, QC, Oct. 13, 2021 /CNW/ - Novartis Pharmaceuticals Canada Inc. today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent...
Clinical trial will study new technology that tracks eye movement to assist diagnosis and monitor disease progression DORVAL, QC, Oct. 5, 2021 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis)...
The Biome Summit 2021 will help fuel debate, drive innovation and advance action on cardiovascular disease as a critical public health issue MONTREAL, Aug. 26, 2021 /CNW/ - Novartis Pharmaceuticals...
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still's disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory...
Expansion of treatment centre network includes two specialized centres in Alberta certified to deliver Kymriah to Canadian patients with relapsed/refractory (r/r) pediatric and young adult B-cell ALL ...
Open feedback by Novartis associates contributed to coveted Canadian employer recognition Novartis ranked among the companies with the highest levels of trust and most inclusive cultures in the...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.